# Chunghwa Chemical Synthesis & Biotech Co., Ltd – FDA 483, Nov 14, 2022

Source: https://www.keypedia.com/records/483/chunghwa-chemical-synthesis-biotech-co-ltd/986c56e6-5168-45f3-8356-c967f620b5af

> FDA 483 for Chunghwa Chemical Synthesis & Biotech Co., Ltd on November 14, 2022. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Chunghwa Chemical Synthesis & Biotech Co., Ltd
- Inspection Date: 2022-11-14
- Product Type: drugs
- Office Name: Office of Biological Products Operations - Division I
- Summary: An FDA inspection of Chunghwa Chemical Synthesis & Biotech Co., Ltd. in New Taipei City, Taiwan, an API manufacturer, revealed significant deficiencies. Observations included inadequate monitoring of the water system's microbial counts, a lack of review for electronic raw data in the chromatography system, and improper extension of retest dates for starting materials without additional testing. These findings indicate a need for improved quality control and data integrity practices.

## Related Documents

- [483 - 2024-04-12](https://www.keypedia.com/records/483/chunghwa-chemical-synthesis-biotech-co-ltd/311a988d-b487-4738-932f-19118ab1ca49) — date: April 12, 2024

## Related Officers

- [Mathematical statistician](https://www.keypedia.com/people/wen-ning-chan/e1f71810-6994-4474-876f-699ea9dee32c)
- [ Investigator ](https://www.keypedia.com/people/matthew-b-casale/e78481c6-5fbd-4723-a79c-167176395af8)

Company: https://www.keypedia.com/companies/chunghwa-chemical-synthesis-biotech-co-ltd/4c8ab291-0275-4884-960a-f5b3bc604eff

Office: https://www.keypedia.com/offices/office-of-biological-products-operations-division-i/49c53dac-7724-4c8c-8708-4f5779ea69c1